Shares of Cellectis Therapeutics were up in trading after the gene-editing pioneer company forged a deal with Cambridge, Mass.-based Cytovia Therapeutics to develop immunotherapies based on gene-edited allogeneic CAR T-cells.
As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.
The U.S. Food and Drug Administration approved G1 Therapeutics’ Cosela (trilaciclib) for injection to decrease the damage to the immune system and bone marrow from chemotherapy.
Merck presented new data from the Phase III CLEAR trial (KEYNOTE-581/Study 307) at the virtual 2021 Genitourinary Cancers Symposium of the company’s checkpoint inhibitor Keytruda (pembrolizumab) and Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) in renal cell carcinoma.
Israel’s largest healthcare provider reported a 94% drop in symptomatic Covid-19 infections among 600,000 people who received two doses of Pfizer’s vaccine in the country’s biggest study to date.
A Covid-19 vaccine candidate developed by Sanofi and U.S. group Translate Bio “will not be ready this year,” the French drugmaker’s chief executive told Le Journal du Dimanche newspaper.
The University of Oxford launched a study to assess the safety and immune response of the Covid-19 vaccine the company has developed with AstraZeneca Plc in children for the first time.
Amicus Therapeutics announced topline results from the Phase III PROPEL pivotal trial of AT-GAA (cipaglucosidase alfa and miglustat) for late-onset Pompe disease.
Texas-based Molecular Templates (MTEM) and Bristol Myers Squibb forged a strategic research collaboration worth a potential $1.3 billion to discover and develop multiple oncology therapies using a next-generation engineered toxin body platform.
Bristol Myers Squibb reported that the company was abandoning the BCMA CAR-T therapy orva-cel and taking a $470 million write-off.
